Company intelligence / Profile preview

Medibio

Ownership: Private
Development stage: Commercial

Overview

Medibio has developed a digital diagnostics platform using circadian heart rate variability and other physiological data to provide objective support in the diagnosis of depression and other mental illnesses. The technology has been validated in over 5,000 patients with ongoing trials to support regulatory approval. Early results suggest high diagnostic accuracy compared to traditional clinical assessments[4][5].

Therapeutic areas: Psychiatry
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Medibio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medibio.

Explore the full profile